How to Achieve Premium Pricing in Europe
Most pharma firms deal with disparate European drug prices by attempting to retain premium pricing in friendlier markets, and exploiting loopholes as best they can elsewhere. But EU enlargement is likely to pull average prices lower still. Before long, the only way to achieve premium prices will be to present compelling health economic data justifying a product's price.
You may also be interested in...
As the global shut-down caused by the coronavirus pandemic continues, sponsors are rushing to adapt clinical trials that can move to partial or completely remote monitoring, allowing patients to remain in their homes but continue to participate in studies. And the outbreak may have another silver lining for the biopharma industry, a chance to rebuild its reputation.
Oncology and rare diseases dominate the industry pipeline, fuelled by science, regulatory tailwinds and high prices. But as the world grapples with coronavirus, and with heart disease still the top killer, can our systems fund treatments for more prevalent conditions?
It has been a bumpy ride for some of the (still modest) number of European biotechs listed on Nasdaq, for various reasons. Yet most expect the direct-to-Nasdaq trend to continue. Europe’s public markets simply cannot compete.